ArriVent BioPharma (AVBP) Earnings Analysis

ArriVent BioPharma (AVBP) next reports earnings on 2026-08-10, consensus EPS -0.98 USD. Last quarter (2026-05-11) it missed with EPS -0.96 USD vs -0.88 USD est (-9.1%). It has beaten estimates in 4/8 recent quarters (50%). Trailing P/E -8.62.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does AVBP next report earnings?

Next earnings date2026-08-10
Consensus EPS estimate-0.98 USD
Revenue estimaten/a

AVBP earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-05-11-0.96 USD-0.88 USD-9.1%Miss
2026-03-05-0.78 USD-0.87 USD+10.3%Beat
2025-11-10-0.83 USD-0.78 USD-6.4%Miss
2025-08-11-0.9 USD-0.7 USD-28.6%Miss
2025-05-12-1.9 USD-0.66 USD-187.9%Miss
2025-03-03-0.6 USD-0.78 USD+23.1%Beat
2024-11-14-0.61 USD-0.82 USD+25.6%Beat
2024-08-14-0.65 USD-0.65 USD0%Beat

Beat rate: 4/8 (50%) over reported quarters with consensus data.

AVBP valuation and analyst view

Trailing P/E-8.62
Trailing EPS-3.22273 USD
Price / book4.23
Dividend yield0.00%
Market cap1.40B
Analyst consensusBuy (7 buy / 0 hold / 0 sell)
Avg price target45 USD

Related research pages

Frequently asked questions

When is ArriVent BioPharma (AVBP)'s next earnings date?

ArriVent BioPharma is next scheduled to report on 2026-08-10, with a consensus EPS estimate of -0.98 USD.

Did AVBP beat earnings last quarter?

In its 2026-05-11 report, AVBP posted EPS of -0.96 USD versus a -0.88 USD estimate — a miss of 9.1%.

What is AVBP's earnings track record?

Over the last 8 reported quarters with consensus data, AVBP beat estimates 4 times (50%).

What is AVBP's current P/E ratio and EPS?

AVBP trades at a trailing P/E of -8.62 on trailing EPS of -3.222732363860576 USD.

What do analysts rate AVBP?

Analyst consensus is "Buy" across 7 ratings (0 strong buy, 7 buy, 0 hold, 0 sell, 0 strong sell). Average 12-month price target: 45 USD.